Welcome to our dedicated page for Solana Company news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Solana Company stock.
Solana Company (NASDAQ: HSDT) generates news across two distinct but connected areas: its neurotech medical device operations and its Solana-focused digital asset treasury strategy. Company press releases and SEC filings highlight developments in clinical research, regulatory submissions, capital markets transactions, and digital asset management.
On the medical device side, Solana Company describes itself as a neurotech company focused on neurologic deficits using an orally applied technology platform to promote neuroplasticity. News items include announcements of positive clinical data related to the PoNS® device and submissions to the U.S. Food and Drug Administration, such as a 510(k) filing for a stroke-related label expansion.
On the digital asset treasury side, Solana Company reports on its efforts to build and manage a treasury of Solana (SOL) tokens. Recent updates have covered a large private investment in public equity (PIPE) financing, the launch of an at-the-market (ATM) program, the approval of a stock repurchase plan, and partnerships with Pantera Capital and Summer Capital. The company also issues news about its SOL holdings, staking performance, and relationships with staking and custody providers, including Helius, Twinstake, Anchorage Digital Bank, and BitGo.
Investors following HSDT news can expect coverage of quarterly financial results, changes in auditors and board composition, applications affecting its reporting status in Canada, and initiatives such as the planned tokenization of HSDT shares on Superstate’s Opening Bell platform. This news page aggregates these disclosures so readers can review Solana Company’s operational, financial, and treasury-related updates in one place.
Helius Medical Technologies (NASDAQ: HSDT) has announced positive results from its PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP), supporting an upcoming FDA submission for treating gait and balance deficits in chronic stroke patients.
The program included three clinical trials with 159 total patients across 10 clinical sites in the US and Canada. The double-blind randomized trial successfully met its primary endpoint, demonstrating statistically significant improvements in gait/balance deficits with active PoNS therapy. The studies showed minimal adverse events and good treatment tolerability.
The company plans to submit an FDA application in Q3 2025 under its current Breakthrough Device Designation, targeting a market of over 7 million stroke patients, of which approximately 80% experience balance and gait deficits.
Helius Medical Technologies (Nasdaq: HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has achieved full compliance with Nasdaq's continued listing requirements. The company received formal confirmation on July 7, 2025 from the Nasdaq Hearings Panel regarding compliance with the equity requirement (Rule 5550(b)(1)).
This follows their earlier compliance confirmation with the minimum bid price requirement (Rule 5550(a)(2)) received on June 3, 2025. The company will be subject to a Mandatory Panel Monitor for one year following this notification.
Helius Medical Technologies (Nasdaq:HSDT) has announced a 1-for-50 reverse stock split of its Class A common stock, effective June 30, 2025. The split will reduce outstanding shares from approximately 33.8 million to 0.7 million, while maintaining the authorized share count at 150 million.
Trading on the split-adjusted basis will begin July 1, 2025, under the same symbol "HSDT" but with a new CUSIP number (42328V 876). The reverse split was approved by stockholders on May 23, 2025, authorizing a ratio range of 1-for-2 to 1-for-250, with the final 1-for-50 ratio determined by the Board of Directors.
Helius Medical Technologies (NASDAQ: HSDT) has secured reimbursement approval from United Healthcare for its Portable Neuromodulation Stimulator (PoNS®) Device, making it the second major healthcare provider after Anthem to offer coverage. The approved reimbursement amount totals $18,100, which includes patient co-payment and represents the adjusted list price for out-of-network status.
The PoNS Device is designed to improve balance and gait deficits while reducing fall risk. This development marks a significant milestone in Helius's strategy to expand patient access through commercial payor coverage and third-party reimbursement, particularly benefiting MS patients.